Incyte Genomics Inc (INCY)
Health Care – SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
- Headquarters
- United States
- Employees
- 2,844
- Market Cap
- $25.8B
About Incyte Genomics Inc
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
SentiSense also tracks daily options readings for Incyte Genomics Inc: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Incyte Genomics Inc stock analysis, sentiment tracking, and market intelligence on SentiSense.